

Brussels | July 04, 2025

Title of the Clinical Trial: **Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)**

Sponsor: European Organisation for Research and Treatment of Cancer (EORTC)

EORTC protocol number: EORTC-1984-BCG

EudraCT number: 2022-003594-33

Protocol: version 1.1 dated 02 December 2022

Concerning: Premature end of trial

The EORTC study 1984-BCG, also known as NOBLE, was prematurely terminated on 27 November 2023, prior to the enrolment of any patients.

This was due to the company's (AstraZeneca) withdrawal of interest in the NOBLE study, due to a focus of their development strategy of PARP-selective inhibitors towards saruparib (AZD5305) versus olaparib. AstraZeneca did not wish to further support this study.

We also confirm hereby that no patients were ever screened, randomised or treated. Therefore, no statistical results were generated.

Yours sincerely,

EORTC Headquarters

